BpV(HOpic)
Based on 7 publication(s) in Google Scholar
BpV(HOpic) is a potent and selective inhibitor of PTEN with an IC50 of 14 nM. Nanocarrier-BpV(HOpic) has neuroprotective activity.
For research use only. We do not sell to patients.
- Purity: 95.0%
- CAS No.: 722494-26-0
- Formula: C6H4K2NO8V
- Molecular Weight:347.24
-
Storage:
-20°C, sealed storage, away from moisture
* The compound is unstable in solutions, freshly prepared is recommended.
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) BpV(HOpic)
More- Nature. 2025 Jan;637(8045):461-469. [Abstract]
- Br J Cancer. 2024 Sep;131(5):944-953. [Abstract]
- Cancer Cell Int. 2021 Dec 19;21(1):689. [Abstract]
- J Mol Cell Cardiol. 2025 Apr 11:S0022-2828(25)00064-1. [Abstract]
- J Mater Sci Mater Med. 2024 Jul 29;35(1):42. [Abstract]
- Biochem Biophys Res Commun. 2022 Oct 30:627:76-83. [Abstract]
- Biochem Genet. 2024 Dec 5. [Abstract]
Customer Validation & Images
-
WB
-
Cell Proliferation/Viability Assay
-
WB
-
Cell Proliferation/Viability Assay
-
WB
Biological Activity
IC50: 14 nM (PTEN)[1]
BpV(HOpic) (1 μM) treatment increases cell proliferation and decreases apoptotic rate in MG63 cells received Cisplatin treatment[3].
Bpv(HOpic) (1 μM) enhances migration of C2C12 myoblasts and is associated with activation of PI3K/AKT and MAPK/ERK signalling pathways[4].
BpV(HOpic) (1 μM; 48 hours) promotes the initiation of swine follicle growth and development, similar as in rodent species and humans[5].
Nanocarrier-BpV(HOpic) enhances axonal outgrowth of neurons[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
BpV(HOpic) (200 μg/kg; i.p.) exacerbates renal dysfunction and promotes tubular damage in mice with ischemia/reperfusion injury (IRI)[7].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Wistar rats are subjected to partial hepatic ischemia[6]
-
Dosage:0.05 mg/kg
-
Administration:I.p. injections at the start of reperfusion
-
Result:Ameliorated reoxygenation injury and reproduced the hepatoprotective effects obtained by adenosine A2A receptor stimulation.
-
Animal Model:Male C57BL/6 mice (8-12 weeks old; 20-30 g ) are subjected to renal ischemia[7]
-
Dosage:200 μg/kg
-
Administration:I.p. injections 1 h before ischemia and then administers every 6 h after ischemia for 24 hr
-
Result:Raised the level of serum creatinine and blood serum urea nitrogen.
Chemical Information
-
CAS No. 722494-26-0
-
Appearance Solid
-
Molecular Weight 347.24
-
Formula C6H4K2NO8V
-
Color Light yellow to yellow
-
SMILES
O=[V+3]12([O-]3)([O-][O-]1)([O-][O-]2)[N]4=CC(O)=CC=C4C3=O.[2 K+]
-
Synonyms
Bisperoxovanadium
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, sealed storage, away from moisture
* The compound is unstable in solutions, freshly prepared is recommended.
Publications (7)
-
Journal Impact Factor
-
Most Recent
-
Nature
2025 Jan;637(8045):461-469. PMID: 39743585
BpV(HOpic) purchased from MedChemExpress. Usage Cited in: Nature. 2025 Jan;637(8045):461-469. [Abstract]
BpV(HOpic) (0.5 mg/kg) .IB analysis of the indicated proteins in liver lysates from above mice. Quantification of relative normalized protein amounts is shown underneath each strip.
-
Br J Cancer
Establishment of a trastuzumab-resistant extramammary Paget disease model: loss of PTEN as a potential mechanism. [Abstract]2024 Sep;131(5):944-953. PMID: 38987365 -
Cancer Cell Int
Imperatorin induces autophagy and G0/G1 phase arrest via PTEN-PI3K-AKT-mTOR/p21 signaling pathway in human osteosarcoma cells in vitro and in vivo. [Abstract]2021 Dec 19;21(1):689. PMID: 34923996
BpV(HOpic) purchased from MedChemExpress. Usage Cited in: Cancer Cell Int. 2021 Dec 19;21(1):689. [Abstract]
BpV(HOpic) (1 μM). Inhibition of PTEN attenuates the inhibitory effect of IMP on the proliferation of 143B and U2OS cells.
BpV(HOpic) purchased from MedChemExpress. Usage Cited in: Cancer Cell Int. 2021 Dec 19;21(1):689. [Abstract]
BpV(HOpic) (1 μM). Western blotting was used to detect the expression levels of key proteins—AKT, p-AKT, mTOR, p-mTOR, p21, CDK6, and LC3—in 143B cells exposed to varying concentrations of IMP and BpV.
-
J Mol Cell Cardiol
2025 Apr 11:S0022-2828(25)00064-1. PMID: 40222552 -
J Mater Sci Mater Med
Mxene-bpV plays a neuroprotective role in cerebral ischemia-reperfusion injury by activating the Akt and promoting the M2 microglial polarization signaling pathways. [Abstract]2024 Jul 29;35(1):42. PMID: 39073469 -
Biochem Biophys Res Commun
Reduced PTCH2 expression is associated with glioma development through its regulation of the PTEN/AKT signaling pathway. [Abstract]2022 Oct 30:627:76-83. PMID: 36027694
BpV(HOpic) purchased from MedChemExpress. Usage Cited in: Biochem Biophys Res Commun. 2022 Oct 30:627:76-83. [Abstract]
The cells proliferation of PBS or BpV(HOpic) (50 nM) treated PTCH2 overexpression LN229/U87 MG cells examined by CCK-8 analysis.
BpV(HOpic) purchased from MedChemExpress. Usage Cited in: Biochem Biophys Res Commun. 2022 Oct 30:627:76-83. [Abstract]
western blotting of phosphorylated and total AKT in L LN229/U87 MG (VEC) and PTCH2 overexpression LN229/U87 MG cells (OE) (treated with PBS or 50 nM BpV(HOpic)).
-
Biochem Genet
2024 Dec 5. PMID: 39638933
Solvent & Solubility
H2O : 50 mg/mL (143.99 mM; ultrasonic and warming and heat to 60°C)
DMSO : 2.89 mg/mL (8.32 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (283 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Schmid AC, et, al. Bisperoxovanadium compounds are potent PTEN inhibitors. FEBS Lett. 2004 May 21; 566(1-3): 35-8. [Content Brief]
[2]. Kim MS, et, al. Nanotherapeutics of PTEN Inhibitor with Mesoporous Silica Nanocarrier Effective for Axonal Outgrowth of Adult Neurons. ACS Appl Mater Interfaces. 2016 Jul 27; 8(29): 18741-53. [Content Brief]
[3]. Zhang B, et, al. Silencing of miR-19a-3p enhances osteosarcoma cells chemosensitivity by elevating the expression of tumor suppressor PTEN. Oncol Lett. 2019 Jan; 17(1): 414-421. [Content Brief]
[4]. Dimchev GA, et, al. Phospho-tyrosine phosphatase inhibitor Bpv(Hopic) enhances C2C12 myoblast migration in vitro. Requirement of PI3K/AKT and MAPK/ERK pathways. J Muscle Res Cell Motil. 2013 May; 34(2): 125-36. [Content Brief]
[5]. Raffel N, et, al. The effect of bpV(HOpic) on in vitro activation of primordial follicles in cultured swine ovarian cortical strips. Reprod Domest Anim. 2019 Aug; 54(8): 1057-1063. [Content Brief]
[6]. Ponte CD, et, al. Pharmacological postconditioning protects against hepatic ischemia/reperfusion injury. Liver Transpl. 2011 Apr; 17(4): 474-82. [Content Brief]
[7]. Zhou J,et, al. Pharmacological Inhibition of PTEN Aggravates Acute Kidney Injury. Sci Rep. 2017 Aug 25; 7(1): 9503. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / H2O | 1 mM | 2.8799 mL | 14.3993 mL | 28.7985 mL | 71.9963 mL |
| 5 mM | 0.5760 mL | 2.8799 mL | 5.7597 mL | 14.3993 mL | |
| H2O | 10 mM | 0.2880 mL | 1.4399 mL | 2.8799 mL | 7.1996 mL |
| 15 mM | 0.1920 mL | 0.9600 mL | 1.9199 mL | 4.7998 mL | |
| 20 mM | 0.1440 mL | 0.7200 mL | 1.4399 mL | 3.5998 mL | |
| 25 mM | 0.1152 mL | 0.5760 mL | 1.1519 mL | 2.8799 mL | |
| 30 mM | 0.0960 mL | 0.4800 mL | 0.9600 mL | 2.3999 mL | |
| 40 mM | 0.0720 mL | 0.3600 mL | 0.7200 mL | 1.7999 mL | |
| 50 mM | 0.0576 mL | 0.2880 mL | 0.5760 mL | 1.4399 mL | |
| 60 mM | 0.0480 mL | 0.2400 mL | 0.4800 mL | 1.1999 mL | |
| 80 mM | 0.0360 mL | 0.1800 mL | 0.3600 mL | 0.9000 mL | |
| 100 mM | 0.0288 mL | 0.1440 mL | 0.2880 mL | 0.7200 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Powered by Bioz